Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$185.16 -0.2%	$185.19	$163.52 ▼ $218.66	$327.31B	0.5	6.24 million shs	12.15 million shs
BMY Bristol Myers Squibb	$46.87 +0.1%	$48.20	$39.35 ▼ $63.33	$95.36B	0.38	12.99 million shs	47.28 million shs
MRK Merck & Co., Inc.	$79.24 -0.1%	$78.89	$73.31 ▼ $134.63	$198.52B	0.38	13.04 million shs	33.83 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	-0.05%	-2.89%	+1.88%	-11.82%	+8.05%
BMY Bristol Myers Squibb	+0.10%	-5.71%	-0.21%	-23.25%	+14.84%
MRK Merck & Co., Inc.	-0.02%	-2.98%	+3.06%	-15.19%	-38.09%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABBV AbbVie	4.923 of 5 stars	3.4	5.0	4.2	3.9	2.8	2.5	1.3
BMY Bristol Myers Squibb	4.939 of 5 stars	3.2	5.0	4.2	4.0	3.0	3.3	1.3
MRK Merck & Co., Inc.	4.997 of 5 stars	3.2	5.0	5.0	3.9	3.0	2.5	3.8

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABBV AbbVie	2.81	Moderate Buy	$211.29	14.11% Upside
BMY Bristol Myers Squibb	2.32	Hold	$58.00	23.75% Upside
MRK Merck & Co., Inc.	2.43	Hold	$109.19	37.79% Upside

Current Analyst Ratings Breakdown

Latest MRK, BMY, and ABBV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	ABBV AbbVie	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold	$205.00
6/9/2025	ABBV AbbVie	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold	$204.00
5/20/2025	MRK Merck & Co., Inc.	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Cautious
5/14/2025	ABBV AbbVie	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$210.00 ➝ $205.00
5/14/2025	MRK Merck & Co., Inc.	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$115.00 ➝ $84.00
5/8/2025	ABBV AbbVie	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
4/29/2025	ABBV AbbVie	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$214.00 ➝ $216.00
4/28/2025	ABBV AbbVie	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$204.00 ➝ $205.00
4/28/2025	ABBV AbbVie	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$241.00 ➝ $250.00
4/25/2025	BMY Bristol Myers Squibb	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
4/25/2025	BMY Bristol Myers Squibb	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform

(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABBV AbbVie	$56.33B	5.81	$14.92 per share	12.41	$1.90 per share	97.45
BMY Bristol Myers Squibb	$48.30B	1.97	$5.89 per share	7.96	$8.08 per share	5.80
MRK Merck & Co., Inc.	$64.17B	3.10	$9.49 per share	8.35	$18.33 per share	4.32

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABBV AbbVie	$4.28B	$2.35	78.79	13.24	1.23	7.31%	412.03%	13.11%	7/24/2025 (Estimated)
BMY Bristol Myers Squibb	-$8.95B	$2.67	17.55	7.70	1.39	11.38%	87.62%	15.98%	7/31/2025 (Estimated)
MRK Merck & Co., Inc.	$17.12B	$6.87	11.53	8.00	0.82	27.27%	43.23%	17.11%	7/29/2025 (Estimated)

Latest MRK, BMY, and ABBV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
4/25/2025	Q1 2025	ABBV AbbVie	$2.40	$2.46	+$0.06	$0.72	$12.91 billion	$13.34 billion
4/24/2025	Q1 2025	BMY Bristol Myers Squibb	$1.50	$1.80	+$0.30	$1.21	$10.77 billion	$11.20 billion
4/24/2025	Q1 2025	MRK Merck & Co., Inc.	$2.16	$2.22	+$0.06	$2.01	$15.59 billion	$15.53 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABBV AbbVie	$6.56	3.54%	N/A	279.15%	53 Years
BMY Bristol Myers Squibb	$2.48	5.29%	N/A	92.88%	17 Years
MRK Merck & Co., Inc.	$3.24	4.09%	N/A	47.16%	14 Years

Latest MRK, BMY, and ABBV Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/20/2025	ABBV AbbVie	quarterly	$1.64	3.54%		7/15/2025	8/15/2025
6/17/2025	BMY Bristol Myers Squibb	quarterly	$0.62	5.25%	7/3/2025	7/3/2025	8/1/2025
5/27/2025	MRK Merck & Co., Inc.	quarterly	$0.81	4.18%	6/16/2025	6/16/2025	7/8/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABBV AbbVie	44.14	0.76	0.64
BMY Bristol Myers Squibb	2.65	1.28	1.17
MRK Merck & Co., Inc.	0.69	1.41	1.16

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABBV AbbVie	70.23%
BMY Bristol Myers Squibb	76.41%
MRK Merck & Co., Inc.	76.07%

Insider Ownership

Company	Insider Ownership
ABBV AbbVie	0.25%
BMY Bristol Myers Squibb	0.09%
MRK Merck & Co., Inc.	0.13%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABBV AbbVie	55,000	1.77 billion	1.76 billion	Optionable
BMY Bristol Myers Squibb	34,100	2.04 billion	2.03 billion	Optionable
MRK Merck & Co., Inc.	75,000	2.51 billion	2.51 billion	Optionable

MRK, BMY, and ABBV Headlines

Recent News About These Companies

4 BofA Securities Strong Buy Growth 10 Stocks Also Pay Reliable Dividends

June 21 at 7:45 AM | 247wallst.com

Intact Investment Management Inc. Has $19.40 Million Stake in Merck & Co., Inc. (NYSE:MRK)

June 21 at 7:43 AM | marketbeat.com

Fishman Jay A Ltd. MI Has $12.76 Million Stake in Merck & Co., Inc. (NYSE:MRK)

June 21 at 7:31 AM | marketbeat.com

Merck & Co., Inc. (NYSE:MRK) Shares Bought by Canton Hathaway LLC

June 21 at 7:08 AM | marketbeat.com

Merck & Co., Inc. (NYSE:MRK) Shares Acquired by Woodmont Investment Counsel LLC

June 21 at 7:00 AM | marketbeat.com

Monte Financial Group LLC Increases Stock Position in Merck & Co., Inc. (NYSE:MRK)

June 21 at 6:50 AM | marketbeat.com

Aspire Private Capital LLC Trims Stake in Merck & Co., Inc. (NYSE:MRK)

June 21 at 6:43 AM | marketbeat.com

Praxis Investment Management Inc. Increases Stake in Merck & Co., Inc. (NYSE:MRK)

June 21 at 6:42 AM | marketbeat.com

Garland Capital Management Inc. Has $4.15 Million Stock Holdings in Merck & Co., Inc. (NYSE:MRK)

June 21 at 6:34 AM | marketbeat.com

World Equity Group Inc. Reduces Stock Holdings in Merck & Co., Inc. (NYSE:MRK)

June 21 at 6:25 AM | marketbeat.com

GAM Holding AG Buys 8,349 Shares of Merck & Co., Inc. (NYSE:MRK)

June 21 at 6:17 AM | marketbeat.com

Stonegate Investment Group LLC Raises Stock Holdings in Merck & Co., Inc. (NYSE:MRK)

June 21 at 6:17 AM | marketbeat.com

Perfromance Wealth Partners LLC Invests $489,000 in Merck & Co., Inc. (NYSE:MRK)

June 21 at 6:08 AM | marketbeat.com

Advocate Group LLC Boosts Stock Position in Merck & Co., Inc. (NYSE:MRK)

June 21 at 5:50 AM | marketbeat.com

Merck & Company (MRK) Gets a Hold from Wells Fargo

June 21 at 3:36 AM | theglobeandmail.com

Cantor Fitzgerald Investment Advisors L.P. Has $13.27 Million Stock Position in Merck & Co., Inc. (NYSE:MRK)

June 20 at 7:19 AM | marketbeat.com

Stableford Capital II LLC Has $1.18 Million Holdings in Merck & Co., Inc. (NYSE:MRK)

June 20 at 6:58 AM | marketbeat.com

Merck & Co., Inc. (NYSE:MRK) Shares Sold by Spirit of America Management Corp NY

June 20 at 6:42 AM | marketbeat.com

Good Steward Wealth Advisors LLC Makes New $688,000 Investment in Merck & Co., Inc. (NYSE:MRK)

June 20 at 6:33 AM | marketbeat.com

Retirement Systems of Alabama Sells 757,134 Shares of Merck & Co., Inc. (NYSE:MRK)

June 20 at 5:56 AM | marketbeat.com

Clark & Stuart Inc Raises Stake in Merck & Co., Inc. (NYSE:MRK)

June 20 at 5:48 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRK, BMY, and ABBV Company Descriptions

AbbVie NYSE:ABBV

$185.16 -0.33 (-0.18%)

Closing price 06/20/2025 03:59 PM Eastern

Extended Trading

$185.64 +0.48 (+0.26%)

As of 06/20/2025 07:59 PM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Bristol Myers Squibb NYSE:BMY

$46.87 +0.03 (+0.06%)

Closing price 06/20/2025 03:59 PM Eastern

Extended Trading

$46.93 +0.06 (+0.13%)

As of 06/20/2025 07:59 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Merck & Co., Inc. NYSE:MRK

$79.24 -0.05 (-0.06%)

Closing price 06/20/2025 03:59 PM Eastern

Extended Trading

$78.72 -0.53 (-0.67%)

As of 06/20/2025 07:59 PM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time